SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
PCSA

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$1.56-$0.13 (-7.69%)
 
Market cap
$4.37M
Insider Score
Health Score
Analyst consensus
Listed since
Mar 7, 2014
Market Cap$4.37M-75.4%
Revenue (ttm)$0
Net Income-$193.16M-1393.5%
EPS-$65.37-92.5%
Shares Out2.80M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume69,954
Open$1.64
Previous Close$1.69
Day's Range$1.39 - $1.66
52-Week Range$1.04 - $8.88
Beta0.97
AnalystsBuy
Price Target$225.00(+14323.08%)
Earnings DateMar 3, 2027
-5.92% (1D)
No price history available.

About PCSA

Processa Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development stage, committed to identifying and progressing therapeutic agents for patients with critical unmet medical requirements throughout the United States. The company's leading investigational drug, PCS499, is an oral tablet presently undergoing Phase 2B clinical assessment. It aims to treat both ulcerative and non-ulcerative manifestations of necrobiosis lipoidica, a chronic and disfiguring dermatological condition. Processa's portfolio also features PCS12852, a unique selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist. This compound is currently in Phase 2A clinical trials for its potential application in managing gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia. Furthermore, the firm is advancing PCS3117, a cytosine analog, which has reached Phase 2B clinical trials for its use in pancreatic cancer and non-small cell lung cancer. Another candidate, PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase, is progressing through Phase 1B clinical trials for metastatic colorectal and breast cancers. In addition, Processa is developing PCS11T, an analog derived from the drugs SN38 and irinotecan, intended for the treatment of diverse cancer types. The company was founded in 2011 and maintains its corporate headquarters in Hanover, Maryland.

Address
601 21st Street, Vero Beach, FL, 32960, US
Market Cap
4 million
Employees
12
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$121.33K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From PCSA’s reported statements · Q3 2026 (trailing 12 months) · 4 of 5 pillars

Next catalysts

1 Day
-7.69%
5 Days
-13.33%
1 Month
-11.36%
6 Months
-39.30%
1 Year
-75.36%

$PCSA stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in PCSA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by PCSA's directors and management

Net Shares Purchased by Insiders−50k−25k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

PCSA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New PCSA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to PCSA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in PCSA

VXFVanguard Extended Market ETF$23.68K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from PCSA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
100% of score
67.3
Analyst Ratings
No data yet
—
News & Sentiment
No data yet
—

Recent Insider Activity

Buys
24
Sells
0
Buy Value
$121.33K
Distinct Buyers
6

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.